FORTREA HOLDINGS DL-,001 Aktie Logo
US34965K1079
A3ECGB
FTRE

FORTREA HOLDINGS DL-,001 Aktie

Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 21,33 € (+19,16 %). La mediana es de 21,38 € (+19,44 %).

Comprar
  7
Mantener
  5
Vender
  1

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Fortrea cooperates with Omico to accelerate biomarker-driven cancer trials in Australia

    Fortrea has announced a collaboration with Omico to advance precision oncology research by accelerating the identification and matching of suitable patients to biomarker-driven clinical trials. The partnership combines Fortrea’s expertise in running oncology studies with Omico’s PrOSPeCT platform, molecular profiling data and a network of investigators and trial sites in Australia. The aim is to optimize study design, enable more targeted site selection and speed patient recruitment using genomic data from more than 23,000 patients. » Más en finanzen.net


  • Fortrea completes acquisition of Worldwide Clinical Trials' early phase services business

    Fortrea has closed the purchase of Worldwide Clinical Trials' early phase services division for about $45 million. The deal includes a 200-bed CRU in San Antonio, a 60,000 sq ft GLP bioanalytical lab in Austin and a sample storage facility in Pflugerville. The acquisition brings Fortrea's global early-phase capacity to more than 570 beds and strengthens internal bioanalytical capabilities to better integrate clinical and analytical processes. It is intended to shorten turnaround times, reduce operational handoffs and expand the platform for clinical development. » Más en finanzen.net


  • Fortrea buys early-phase unit from Worldwide for $45 million

    Fortrea has signed an agreement to acquire the early‑phase division of Worldwide Clinical Trials for about $45 million in cash. The acquisition includes a 60,000‑square‑foot bioanalytical lab in Austin, a 200‑bed clinic in San Antonio and a biospecimen storage facility in Pflugerville. Fortrea thereby strengthens its Clinical Pharmacology Services and expands capacity for bioanalysis of large and small molecules, while the transaction still requires regulatory and licensing approvals. Both companies plan transition agreements to ensure continuity for customers and ongoing programs. » Más en de.investing.com


  • Fortrea introduces Fortrea Intelligent Technology, an AI-powered suite to accelerate clinical trials

    Fortrea has introduced Fortrea Intelligent Technology (FIT), a suite of people-centered, AI-powered solutions to automate workflows, optimize monitoring, and accelerate clinical trials. FIT builds on the Xcellerate platform and offers applications for biopharma, biotechnology, and medical device companies in full-service, functional-service, and SaaS models. The suite is organized into three pillars — lifecycle, foresight, and support — and provides role-based insights in near real time to improve predictability, quality, and productivity. » Más en finanzen.net


  • Fortrea launches AI-powered technology suite Fortrea Intelligent Technology to support clinical trials

    Fortrea introduced Fortrea Intelligent Technology (FIT), an AI-powered suite that includes extensions to the Xcellerate platform and new Lifecycle, Foresight and Companion modules. The tools automate workflows, integrate study data for role-specific insights and use AI/ML for pattern analysis and predictive signal generation; selected components will be offered as SaaS. The announcement comes as the stock trades below $10 and analysts project a return to profitability. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, FORTREA HOLDINGS DL-,001 Aktie tuvo unos ingresos de 610,49 M € y un beneficio neto de 529,71 mil €
(EUR) septiembre de 2026
YoY
Ingresos 610,49 M 2,16 %
Beneficio bruto 123,16 M 40,18 %
Beneficio neto 529,71 mil 103,91 %
EBITDA 32,31 M 180,88 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
1686,11 M €
Número de acciones
94,6 M
Máximo/mínimo de 52 semanas
23,80 € - 7,78 €
Dividendos No
Beta
1,86
Ratio P/E
-25,99
Ratio PEG
-0,11
Ratio P/B
3,52
Ratio P/S
0,69

Perfil de la empresa

Fortrea Holdings Inc. proporciona soluciones de desarrollo clínico y acceso de pacientes a la industria de las ciencias de la vida. Ofrece gestión de ensayos clínicos de fase I-IV, farmacología clínica, soluciones de ensayos diferenciadas habilitadas por tecnología y servicios posteriores a la aprobación. La compañía atiende a organizaciones farmacéuticas, biotecnológicas y de dispositivos médicos. Fortrea Holdings Inc. tiene su sede en Durham, Carolina del Norte.

Nombre
FORTREA HOLDINGS DL-,001 Aktie
CEO
Anshul Thakral
Sede Durham, nc
Estados Unidos
Sitio web
Industria
Equipos y suministros sanitarios
Salida a bolsa
20/06/2023
Empleados 14.000

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
FTRE
Frankfurt
K67.F
Düsseldorf
K67.DU
München
K67.MU
🍪

Parqet  usa cookies. Más información